broadspectrum
antivir
drug
urgent
need
treat
individu
infect
new
reemerg
virus
virus
develop
resist
antivir
therapi
mammalian
natur
host
defens
peptid
mnhp
short
usual
cation
peptid
direct
antimicrobi
activ
instanc
activ
cellmedi
antivir
immun
respons
although
mnhp
potent
activ
vitro
efficaci
trial
vivo
exogen
provid
mnhp
larg
disappoint
mnhp
current
licens
human
use
mastoparan
invertebr
host
defens
peptid
penetr
lipid
bilay
reason
mastoparan
analog
might
interact
lipid
compon
viru
membran
therebi
reduc
infect
envelop
virus
object
determin
whether
mastoparanderiv
peptid
could
inactiv
virus
multipl
type
whether
could
stimul
cellmedi
antivir
activ
found
potent
inactiv
rang
envelop
virus
consist
propos
mechan
action
efficaci
nonenvelop
viru
pretreat
cell
reduc
amount
viru
recov
infect
suggest
primari
mechan
action
vitro
direct
inactiv
viru
result
demonstr
first
time
mastoparan
deriv
broadspectrum
antivir
activ
vitro
suggest
investig
antivir
properti
mastoparan
peptid
vivo
warrant
press
need
identifi
novel
broadspectrum
antimicrobi
agent
use
therapeut
treat
emerg
multidrug
resist
bacteri
viral
pathogen
past
decad
natur
host
defens
peptid
nhp
produc
plant
invertebr
vertebr
anim
emerg
promis
class
antimicrobi
host
defens
peptid
compris
broad
array
endogen
peptid
antibiot
produc
either
constitut
respons
wound
mechan
stress
inflamm
microbi
infect
signific
advantag
nhp
type
antimicrobi
although
resist
nhp
induc
vitro
exist
natur
rare
instanc
occur
rate
order
magnitud
lower
convent
antimicrobi
undertook
present
studi
determin
whether
put
host
defens
peptid
deriv
wasp
peptid
mastoparan
antivir
properti
although
antibacteri
antifung
properti
invertebr
nhp
well
studi
small
number
report
ascrib
antivir
activ
invertebr
peptid
mastoparan
venom
compon
may
also
contribut
acellular
immun
defens
pathogen
manner
better
character
cecropin
attacin
insect
review
consist
idea
mastoparan
induc
exocytosi
hemocyt
primari
mediat
immun
defens
invertebr
addit
mastoparanb
isol
hornet
vespa
basali
restrict
growth
variou
gram
posit
neg
bacteria
vitro
final
sever
molecular
featur
mastoparan
peptid
suggest
might
effect
antimicrobi
agent
mastoparan
unstructur
aqueou
medium
form
amphipath
contact
lipid
perpendicular
insert
mastoparan
lipid
membran
synthet
vesicl
load
dye
transient
open
pore
dye
releas
intermitt
mastoparan
also
trigger
mast
cell
degranul
vitro
activ
gprotein
receptor
histamin
chemokin
prostaglandin
signal
heterotrimer
g
protein
review
mastoparan
would
therefor
expect
divers
effect
immun
respons
vivo
reason
hypothes
mastoparanderiv
peptid
analog
enhanc
activ
rel
parent
peptid
mastoparan
might
abl
reduc
infect
envelop
virus
directli
via
disrupt
envelop
structur
might
also
promot
cellmedi
antivir
respons
studi
describ
help
guid
futur
develop
mastoparanderiv
peptid
antivir
agent
vivo
ethic
statement
anim
studi
review
approv
duke
univers
institut
anim
care
use
committe
eight
tenweekold
femal
mice
obtain
charl
river
laboratori
hous
least
week
experi
initi
mice
hous
microisol
cage
biosafeti
level
anim
facil
viral
stock
dilut
appropri
titer
serumfre
dmem
intranas
inocul
mice
lightli
anesthet
isofluran
use
vapor
administ
pfu
vsv
presenc
absenc
indic
total
volum
infect
anim
monitor
twice
daili
develop
symptom
mice
weigh
daili
human
euthan
lost
preinfect
bodi
weight
institut
anim
care
use
committe
duke
univers
approv
anim
experi
cell
babi
hamster
kidney
atcc
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
calf
serum
penicillinstreptomycin
dmem
unless
otherwis
indic
bhk
cell
use
propag
titer
vesicular
stomat
viru
vsv
indiana
strain
vero
cell
african
green
monkey
kidney
cell
atcc
cultur
dmem
supplement
fetal
calf
serum
penicillinstreptomycin
dmem
use
propag
titer
herp
simplex
viru
west
nile
viru
strain
wnv
yellow
fever
viru
strain
chimer
viru
cell
african
green
monkey
kidney
cell
atcc
cultur
dmem
use
propag
titer
vaccinia
viru
western
reserv
vvwr
cowpox
brighton
red
cpxvbr
cell
atcc
cultur
meme
supplement
fetal
calf
serum
penicillinstreptomycin
nonessenti
amino
acid
sodium
pyruv
meme
use
propag
titer
human
respiratori
syncyti
viru
rsv
cell
human
lung
epitheli
cell
atcc
cultur
dmem
use
propag
titer
adenoviru
adv
raw
cell
abelson
murin
leukemia
viru
transform
macrophag
cell
atcc
cultur
meme
mdck
cell
madindarbi
canin
kidney
atcc
cultur
meme
use
influenza
tcid
assay
peptid
inlkalaalakallnh
synthes
cpc
scientif
sunnydal
ca
virus
incub
total
volum
serumfre
dmem
indic
concentr
peptid
incub
room
temperatur
unless
otherwis
indic
allow
proceed
min
vortex
everi
min
unless
otherwis
note
end
incub
period
ml
serumfre
dmem
ad
sampl
lower
peptid
concentr
sampl
serial
dilut
appli
monolay
appropri
cell
type
determin
viru
plaqu
assay
describ
influenza
titer
determin
tcid
assay
follow
mdck
cell
microtit
plate
infect
serial
dilut
viruscontain
supernat
tcid
determin
day
later
method
reed
muench
infect
well
identifi
presenc
absenc
agglutin
turkey
red
blood
cell
ad
well
percent
reduct
infect
determin
viru
follow
reduct
titer
titer
peptid
treat
sampl
pfuml
titer
untreat
sampl
pfuml
vsv
stock
concentr
airfug
beckman
fullerton
ca
centrifug
psi
min
supernat
remov
replac
mosmol
hepe
buffer
salin
hb
centrifug
buffer
exchang
repeat
viru
resuspend
hb
multipl
tube
combin
mix
resuspend
viru
treat
final
concentr
final
volum
incub
carri
min
rt
incub
viru
immobil
carbonco
formvar
mesh
grid
remov
blot
wash
water
blot
grid
stain
uranyl
acet
remov
blot
viru
imag
use
philipsfei
cm
transmiss
electron
microscop
microscopi
perform
duke
electron
microscopi
servic
bhk
cell
cellswel
plate
well
flat
bottom
tissu
cultur
plate
allow
attach
overnight
cell
treat
serumfre
media
contain
concentr
min
h
peptidecontain
media
remov
well
wash
phenol
redfre
media
prior
addit
mt
inner
salt
reagent
cell
viabil
assess
use
celltit
aq
ueou
assay
promega
madison
wi
follow
manufactur
protocol
absorb
read
nm
use
multidetect
micropl
reader
biotek
highland
park
usa
assay
cellmedi
antivir
activitysemiconflu
monolay
three
differ
cell
type
raw
cellswel
well
plate
wash
serumfre
dmem
sfdmem
incub
peptid
total
volum
ml
sfdmem
h
peptid
remov
cell
wash
sfdmem
cell
infect
pfu
per
well
vsv
moi
total
volum
min
adsorpt
inoculum
remov
cell
wash
sfdmem
ml
complet
medium
contain
fetal
bovin
serum
ad
well
supernat
collect
h
infect
titer
via
plaqu
assay
bhk
cell
describ
elisa
bind
antibodyeasywash
high
bind
elisa
plate
well
polystyren
corn
coat
purifi
cpxv
ng
per
well
bicarbon
buffer
nahco
overnight
well
wash
block
superblock
normal
goat
serum
whey
pbstween
incub
dilut
sera
antibodi
detect
alkalinephosphatas
conjug
goat
antimous
ig
antibodi
reactiv
detect
ad
pnpp
substrat
phosphat
sigma
mgml
direct
manufactur
incub
min
read
ab
nm
serum
ig
endpoint
titer
report
reciproc
highest
dilut
gave
absorb
greater
background
background
absorb
preimmun
serum
dilut
anim
assay
individu
compar
individu
preimmun
titer
determin
whether
mastoparan
analog
peptid
antivir
properti
incub
increas
concentr
pfu
vesicular
stomat
viru
indiana
vsv
assay
residu
infect
viru
via
plaqu
assay
bhk
cell
incub
perform
room
temperatur
total
volum
serum
free
medium
sampl
vortex
everi
min
promot
mix
viru
peptid
min
incub
reaction
stop
via
addit
ml
serum
free
medium
serial
dilut
made
ml
cultur
dilut
appli
bhk
cell
detect
residu
infecti
viru
plaqu
assay
shown
fig
peptid
concentr
reduc
elimin
infect
vsv
degre
inactiv
complet
rel
higher
peptid
concentr
fewer
input
virion
use
inactiv
also
effici
incub
time
increas
fig
result
suggest
instanc
viru
inactiv
depend
upon
direct
contact
viru
peptid
could
occur
cell
free
system
studi
report
antimicrobi
properti
cation
peptid
affect
chang
temperatur
presenc
serum
serum
protein
determin
whether
factor
affect
direct
antivir
activ
perform
inactiv
studi
differ
temperatur
shown
fig
abil
inactiv
vsv
increas
rel
warmer
temperatur
decreas
cooler
temperatur
observ
agre
report
show
increas
antivir
activ
peptid
antibiot
higher
temperatur
rais
possibl
direct
viru
inactiv
might
facilit
increas
fluiditi
viru
envelop
lipid
higher
incub
temperatur
determin
whether
presenc
bovin
serum
affect
direct
antivir
activ
perform
direct
inactiv
vsv
media
contain
differ
amount
nonheat
inactiv
fetal
calf
serum
experi
perform
four
time
repres
result
shown
fig
studi
consist
show
serum
concentr
decreas
abil
inactiv
vsv
although
activ
retain
media
contain
serum
compar
favor
report
nhp
complet
inact
serum
concentr
suggest
might
retain
antivir
activ
vivo
preced
studi
demonstr
treatment
could
reduc
infect
vsv
vitro
dose
time
depend
manner
determin
whether
vsv
inactiv
pathogen
vivo
challeng
group
mice
n
per
group
intranas
pfu
recombin
vsv
express
model
vaccin
antigen
cowpox
protein
cpxv
either
preincub
min
mice
infect
intranas
live
vsv
display
clinic
sign
acut
ill
lose
preinfect
bodi
weight
first
four
day
challeng
shown
fig
mice
infect
untreat
vsv
lost
approxim
preinfect
bodi
weight
second
day
challeng
open
circl
fig
fulli
regain
preinfect
weight
five
day
challeng
contrast
mice
infect
vsv
preincub
fill
circl
fig
lose
significantli
weight
mockchalleng
control
mice
p
twotail
student
test
time
studi
exhibit
clinic
sign
ill
differ
weight
loss
two
vsv
infect
group
signific
day
infect
p
twotail
student
test
mice
inocul
treat
vsv
lose
significantli
less
weight
inocul
untreat
viru
result
support
idea
vsv
preincub
noninfecti
could
replic
vivo
second
measur
detect
residu
infect
vivo
use
bind
elisa
detect
serum
antibodi
reactiv
vaccin
antigen
encod
vsv
encod
viral
rna
produc
result
viru
replic
present
outer
envelop
vsv
particl
inoculum
thu
mice
develop
detect
immun
respons
could
infer
amount
infecti
viru
present
inoculum
shown
fig
mice
infect
treat
viru
significantli
reduc
antibodi
respons
rel
receiv
untreat
viru
p
via
unpair
test
fig
timepoint
respons
measur
two
four
mice
infect
treat
vsv
develop
detect
antibodi
timepoint
test
supplement
fig
two
mice
treat
vsv
group
develop
low
titer
ab
suggest
virion
inoculum
inactiv
peptid
pretreat
capabl
replic
anim
host
test
idea
inoculum
like
residu
infecti
virion
incub
number
vsv
particl
use
infect
mice
total
volum
min
transfer
entir
inoculum
cm
plate
bhk
cell
allow
inoculum
adsorb
min
ml
serum
free
media
ad
ml
complet
media
allow
infect
proceed
overnight
total
h
shown
fig
titer
supernat
collect
cell
detect
infecti
viru
albeit
significantli
reduc
amount
vs
produc
cell
infect
nontreat
viru
support
idea
small
amount
infecti
viru
remain
inoculum
use
infect
mice
fig
b
infecti
viru
gave
rise
immun
respons
observ
supplementari
data
associ
articl
found
onlin
version
http
preced
data
show
could
inactiv
vsv
address
whether
might
broadspectrum
activ
virus
test
idea
perform
direct
inactiv
studi
use
pfu
virus
shown
tabl
studi
peptid
concentr
kept
constant
reaction
volum
peptid
viru
incub
room
temperatur
min
min
incub
residu
infect
assay
via
plaqu
assay
virus
except
influenza
residu
infect
determin
tcid
appropri
mammalian
cell
line
specifi
method
limit
detect
infecti
viru
plaqu
assay
pfuml
experi
conduct
least
three
time
confirm
result
shown
tabl
abl
reduc
elimin
infect
eight
ten
envelop
virus
test
reduc
infect
nonenvelop
adenoviru
virus
infect
reduc
treatment
enter
cell
via
common
mechan
via
common
receptor
result
suggest
mechan
action
inactiv
via
bind
peptid
specif
molecul
eg
viral
attach
protein
rather
via
interfer
process
common
envelop
virus
eg
fusion
viral
envelop
host
cell
plasma
endosom
membran
parent
peptid
mastoparan
shown
bind
penetr
cell
membran
synthet
lipid
bilay
eg
liposom
therefor
hypothes
might
inactiv
envelop
virus
insert
viru
envelop
therebi
disrupt
envelop
structur
interf
viru
bind
andor
fusion
process
begin
test
idea
use
transmiss
electron
microscopi
tem
examin
morpholog
vsv
virion
incub
shown
fig
treatment
caus
signific
disrupt
virion
structur
low
concentr
peptid
envelop
appear
separ
capsid
remain
attach
either
end
virion
fig
c
higher
peptid
concentr
fig
e
peptid
treatment
caus
complet
dissoci
envelop
leav
nake
capsid
intact
case
viral
particl
complet
broken
apart
viral
rna
extend
end
disrupt
virion
although
viru
use
tem
analysi
could
directli
assay
infect
morpholog
chang
observ
would
expect
render
viru
noninfecti
data
support
model
confirm
could
affect
virion
integr
cellindepend
manner
forgo
studi
demonstr
could
alter
viru
infect
cell
free
environ
exclud
possibl
peptid
could
also
act
upon
host
cell
make
resist
infect
less
permiss
viral
replic
one
barrier
address
question
directli
mastoparan
mastoparanderiv
peptid
cytotox
high
concentr
part
mastoparan
trigger
releas
proapoptot
mediat
mitochondria
began
determin
maximum
concentr
caus
morpholog
chang
loss
viabil
cell
line
interest
cell
shown
fig
incub
cell
rel
high
concentr
caus
rapid
morpholog
chang
bleb
plasma
membran
cell
round
bhk
cell
could
readili
visual
light
microscopi
incub
cell
concentr
caus
visibl
morpholog
chang
even
h
cultur
data
shown
confirm
lower
concentr
caus
toxic
evid
visual
inspect
perform
assay
measur
mitochondri
activ
shown
fig
incub
cell
concentr
result
signific
differ
cell
viabil
treat
untreat
sampl
even
cell
incub
h
meant
could
pretreat
cell
concentr
without
compromis
cell
viabil
assay
determin
whether
nh
could
promot
cellmedi
antivir
activ
preincub
cell
h
infect
pfu
vsv
measur
amount
viru
supernat
h
infect
shown
fig
pretreat
bhk
cell
h
infect
significantli
reduc
amount
viru
recov
supernat
infect
cell
graph
show
result
three
independ
experi
data
show
promot
robust
cellmedi
antivir
activ
cell
exclud
possibl
might
act
cell
type
render
resist
viral
infect
shown
express
pathogen
recognit
receptor
tlr
nlr
determin
whether
interferon
compet
cell
line
express
pathogen
recognit
receptor
might
abl
restrict
viral
entryrepl
treatment
repeat
studi
use
lung
epitheli
cell
macrophag
cell
shown
fig
c
peptid
pretreat
cell
significantli
decreas
amount
viru
releas
cell
p
p
respect
via
pair
twotail
test
although
treat
cell
alway
produc
slightli
reduc
amount
viru
rel
untreat
cell
undertook
studi
goal
determin
whether
cation
peptid
deriv
wasp
venom
peptid
mastoparan
antivir
activ
character
peptid
import
natur
host
defens
peptid
nhp
potenti
serv
broadspectrum
antivir
agent
antivir
drug
broad
reactiv
urgent
need
two
drug
current
licens
human
use
ribavirin
interferon
caus
signific
side
effect
treat
individu
neither
effect
emerg
virus
west
nile
viru
avian
influenza
henipavirus
found
potent
inactiv
envelop
virus
five
differ
famili
cellfre
system
vitro
measur
reduc
infect
nonenvelop
adenoviru
result
confirm
potent
broadspectrum
antivir
activ
support
idea
act
interf
share
process
structur
essenti
infect
envelop
nonenvelop
virus
use
prototyp
viru
vsv
determin
minimum
virucid
concentr
found
still
retain
activ
concentr
low
although
difficult
directli
compar
result
report
group
appear
activ
compar
favor
invertebr
peptid
test
exampl
modifi
nhp
use
reduc
infecti
titer
measl
viru
reduc
infecti
titer
vsv
log
depend
upon
amount
input
viru
fig
addit
found
activ
physiolog
temperatur
retain
activ
albeit
reduc
level
presenc
serum
protein
import
mani
mammalian
antimicrobi
peptid
potent
activ
serumfre
media
either
partial
complet
inact
presenc
serum
result
encourag
led
us
investig
mechan
exert
antivir
effect
virus
inactiv
share
common
cellular
receptor
enter
host
cell
mechan
util
type
nucleic
acid
genom
rna
vs
dna
reason
physic
disrupt
envelop
might
contribut
direct
viru
inactiv
inde
subject
nh
treat
vsv
virion
electron
microscopi
found
envelop
separ
core
virion
case
complet
detach
nucleocapsid
result
agre
howel
et
al
report
vaccinia
viru
treat
mammalian
host
defens
peptid
perturb
envelop
structur
result
fit
predict
model
peptidemedi
viru
inactiv
rais
question
fail
inactiv
influenza
virus
inactiv
rsv
less
effect
vsv
flavivirus
influenza
viru
stock
grown
egg
one
possibl
trace
amount
allanto
fluid
viru
prepar
could
inhibit
activ
howev
ad
allanto
fluid
directinactiv
reaction
vsv
observ
reduct
efficaci
suggest
presenc
allanto
fluid
protein
factor
resist
influenza
mediat
inactiv
altern
possibl
differ
rel
plastic
viru
envelop
made
virus
resist
inactiv
other
exampl
vsv
flavivirus
highli
order
envelop
structur
viru
attach
andor
fusion
protein
anchor
regular
pattern
among
lipid
viru
envelop
contrast
influenza
rsv
virion
rel
pleomorph
attach
fusion
protein
assum
less
order
array
within
lipid
bilay
plastic
might
render
flu
rsv
resist
perturb
envelop
structur
ie
insert
peptid
alter
shape
curvatur
virion
attach
fusion
might
still
possibl
anoth
possibl
differ
lipid
composit
variou
viru
envelop
may
render
virus
resist
other
inactiv
shown
select
cytotox
polybia
mastoparan
depend
lipid
composit
plasma
membran
phosphatidylserin
protect
phosphatidylcholin
rich
membran
suscept
damag
test
hypothes
prioriti
futur
studi
ultim
goal
abl
predict
activ
mp
deriv
virus
base
structur
fluiditi
viru
envelop
second
question
inactiv
cowpox
vaccinia
viru
less
effect
vsv
flavivirus
unlik
envelop
virus
test
singl
type
infecti
particl
surround
singl
bilaminar
envelop
poxvirus
exist
four
differ
infecti
form
intracellular
matur
virion
imv
account
major
infecti
particl
singl
lipid
envelop
howev
intracellular
envelop
virion
iev
usual
second
numer
particl
laboratori
prepar
viru
acquir
addit
envelop
layer
migrat
toward
plasma
membran
via
golgi
andor
endosom
presum
envelop
iev
would
difficult
penetr
disrupt
inde
work
howel
et
al
disrupt
vaccinia
viru
envelop
appear
much
less
extens
observ
vsv
although
differ
could
due
factor
consist
idea
substanti
envelop
structur
might
render
virus
resist
inactiv
peptid
share
mode
action
anoth
goal
studi
determin
whether
could
trigger
cellmedi
antivir
activ
mani
nhp
shown
induc
andor
enhanc
innat
immun
respons
host
exampl
pretreat
cell
human
defensin
render
cell
less
permiss
viral
replic
induc
express
ifnrespons
gene
suppress
upregul
cellular
pkc
requir
influenza
viru
replic
nuclear
traffick
hand
pretreat
cell
three
differ
lineag
prevent
infect
cell
vsv
reduc
amount
viru
produc
infect
cell
one
consider
interpret
result
howev
system
vitro
use
singl
cell
type
cultur
whole
anim
rang
cell
type
would
expect
respond
peptid
treatment
indirect
cellmedi
antivir
activ
might
induc
predict
support
result
king
et
al
examin
immunolog
respons
wasp
venom
found
mice
immun
mastoparan
anoth
venom
protein
enhanc
antivenom
ige
respons
vs
receiv
venom
protein
alon
sum
find
demonstr
potent
broadspectrum
antivir
activ
vitro
activ
physiolog
condit
cellfre
system
treatment
virion
significantli
disrupt
integr
viru
envelop
result
demonstr
first
time
antivir
properti
mastoparanderiv
peptid
add
understand
mechan
natur
host
defens
peptid
inactiv
viral
pathogen
refer
web
version
pubm
central
supplementari
materi
vsv
inactiv
treatment
caus
diseas
vivo
group
mice
n
mice
per
group
challeng
intranas
pfu
treat
untreat
vsv
total
volum
mice
weigh
daili
inocul
graph
panel
repres
averag
percent
initi
weight
group
star
indic
timepoint
averag
weight
mice
receiv
untreat
vsv
significantli
lower
p
twotail
test
averag
weight
mice
receiv
treat
vsv
panel
b
show
serum
antibodi
titer
group
day
infect
measur
elisa
recombin
protein
coat
antigen
bar
graph
repres
geometr
mean
titer
immun
group
error
bar
denot
upper
lower
limit
confid
interv
titer
significantli
lower
mice
immun
peptid
treat
vs
untreat
viru
three
timepoint
p
day
p
day
p
day
via
unpair
test
studi
perform
twice
consist
result
panel
c
pfu
vsv
incub
room
temperatur
min
min
whole
inoculum
plate
bhk
cell
allow
grow
overnight
total
volum
ml
amount
viru
cell
cultur
supernat
hr
determin
plaqu
assay
graph
show
total
number
infecti
virion
detect
supernat
repres
averag
three
experi
perform
independ
treatment
disrupt
envelop
structur
vsv
virion
treat
indic
concentr
neg
stain
tem
untreat
vsv
virion
typic
bullet
morpholog
viru
core
surround
intact
envelop
panel
fill
arrowhead
envelop
virion
treat
disrupt
separ
viru
core
panel
b
c
fill
arrow
envelop
virion
treat
complet
dissoci
core
mani
case
envelop
aggreg
one
end
core
panel
e
empti
arrow
imag
shown
two
independ
experi
pretreat
cell
significantli
reduc
amount
viral
progeni
releas
infect
cell
indic
cell
type
either
pretreat
h
fill
circl
incub
serumfre
medium
without
peptid
open
circl
total
volum
ml
h
incub
media
remov
cell
wash
infect
pfu
vsv
moi
sfdmem
h
inoculum
remov
replac
fb
supernat
collect
h
titer
via
plaqu
assay
cell
measur
amount
viru
releas
graph
show
result
three
independ
studi
cell
line
differ
amount
viru
releas
treat
vs
untreat
cell
significantli
differ
three
cell
type
test
